Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639030 | 1.00 | IDO1 (0.53) | IDO1FFAR1GPR84ATMPTGDR2 | |
| SCHEMBL9363921 | 0.91 | IDO1 (0.55) | IDO1FFAR1GPR84PTGDR2 | |
| SCHEMBL11658615 | 0.86 | IDO1 (0.56) | IDO1FFAR1GPR84ATMCYP11B1 | |
| SCHEMBL11025088 | 0.82 | HTR2C (0.49) | IDO1FFAR1GPR84ATMHTR2C | |
| Acetic Acid SCHEMBL27529459 | 0.81 | FFAR1 (0.52) | IDO1FFAR1GPR84ATMPIN1 | |
| SCHEMBL11258276 | 0.81 | FFAR1 (0.46) | IDO1FFAR1GPR84PIN1 | |
| SCHEMBL1746407 | 0.80 | FFAR1 (0.60) | IDO1FFAR1PTGDR2 | |
| SCHEMBL7846356 | 0.80 | HTR2C (0.53) | IDO1FFAR1GPR84HTR2CSLC6A3 | |
| SCHEMBL7258599 | 0.79 | IDO1 (0.63) | IDO1GPR84CYP11B2 | |
| SCHEMBL31072335 | 0.78 | IDO1 (0.50) | IDO1FFAR1ATMHTR2CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020227344-A1 | CHLORIDE INTRACELLULAR CHANNEL 1 FOR REGULATION OF FOOD INTAKE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-12 | — | — | WO | claimed |
| EP-2934110-B1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIV GENT (BE) | 2018-08-01 | — | — | EP | claimed |
| US-9485983-B2 | Use of connexin channel inhibitors to protect grafts | UNIVERSITEIT GENT (BE) | 2016-11-08 | — | — | US | claimed |
| US-20150313208-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIVERSITEIT GENT (BE) | 2015-11-05 | — | — | US | claimed |
| EP-2934110-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | Universiteit Gent (BE) | 2015-10-28 | — | — | EP | claimed |
| WO-2014095468-A1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIVERSITEIT GENT (BE) | 2014-06-26 | — | — | WO | claimed |
| US-20140024683-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-01-23 | — | — | US | claimed |
| WO-2012134965-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-10-04 | — | — | WO | claimed |
| US-20100168030-A1 | Methods and compositions for treatment of organophosphate-caused pathology | ARMY, UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE | 2010-07-01 | — | — | US | claimed |
| US-20090220516-A1 | Neuroprotection of retinal ganglion cells | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2009-09-03 | — | — | US | claimed |
| WO-2007002139-A2 | NEUROPROTECTION OF RETINAL GANGLION CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-01-04 | — | — | WO | claimed |
| EP-0786994-B1 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-5705530-A | SIDE EFFECT REDUCTION; GLAUCOMA TREATMENT | ALLERGAN (US) | 1998-01-06 | — | — | US | claimed |
| EP-0786994-A2 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | Allergan (US) | 1997-08-06 | — | — | EP | claimed |
| US-5559151-A | Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers | ALLERGAN (US) | 1996-09-24 | — | — | US | claimed |
| WO-1996016647-A2 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN (US) | 1996-06-06 | — | — | WO | claimed |
| EP-0330380-B1 | NOVEL INDANOXYACETIC ACID DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 1993-06-23 | — | — | EP | claimed |
| US-4975460-A | INHIBITION OF PLATELET AGGREGATION | TANABE SEIYAKU CO., LTD. (JP) | 1990-12-04 | — | — | US | claimed |
| EP-0330380-A2 | Novel indanoxyacetic acid derivatives and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1989-08-30 | — | — | EP | claimed |
| US-4334088-A | 2-Alkynyl-5-indanyloxyacetic acids | MEAD JOHNSON & COMPANY (US) | 1982-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024683-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | CLCN2, SLC6A1, SLC26A3 | IDO1 3703/4885FFAR1 1336/4885GPR84 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.